BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

603392

CNE100004090

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
68.26 ^CNY	+7.67%		+1.46%	-9.14%

Apr. 25	Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 12	Wantai Biological's Phase 3 Trials for Nine-Valent HPV Vaccine Yields Performed 'As Expected'	MT

Xiamen Innovax Biotech CO., LTD. announced that it has received CNY 400 million in funding from Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

July 22, 2022

On July 23, 2022, Xiamen Innovax Biotech CO., LTD. closed the transaction.

Latest news about Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Wantai Biological's Phase 3 Trials for Nine-Valent HPV Vaccine Yields Performed 'As Expected'	Apr. 12	MT
Wantai BioPharm's 2023 Profit Drops 74% on Revenue Drop; Shares Slump 3%	Mar. 29	MT
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Wantai Biological Pharmacy Predicts Up to 75% Profit Decline in 2023	Jan. 24	MT
Sinovac Halts Production of COVID-19 Vaccine as Demand Wanes	Jan. 12	MT
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China	Jan. 10	MT
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. announces an Equity Buyback for CNY 400 million worth of its shares.	23-09-22	CI
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. authorizes a Buyback Plan.	23-08-27	CI
Wantai Biological Pharmacy's Profit Drops 36.8% in H1	23-08-25	MT
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Wantai Biological Pharmacy’s Profit Slides 6.5% in Q1 as Revenue Falls 9%	23-04-20	MT
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-20	CI
Wantai BioPharm Enrolls First Subjects for Pneumonia Vaccine Trial	23-02-14	MT
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-01-19	CI
Tranche Update on Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.'s Equity Buyback Plan announced on August 6, 2022.	22-12-22	CI
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.'s Equity Buyback announced on August 6, 2022, has expired with 1,585,320 shares, representing 0.17% for CNY 200.17 million.	22-12-20	CI
China's super-rich see fortunes plunge as economy slows	22-11-07	RE
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-17	CI
Wantai Biological Pharmacy Sees Up to 232% Profit Growth in January-September Period	22-10-12	MT
Wantai Biological Pharmacy’s H1 Profit Nearly Quadruples, Meeting Target	22-08-26	MT
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. announces an Equity Buyback for CNY 400 million worth of its shares.	22-08-05	CI
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. authorizes a Buyback Plan.	22-08-04	CI

Chart Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Duration

Period

Chart Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

More charts

Beijing Wantai Biopharmaceutical Co., Ltd. is a company mainly engaged in the research and development, production and sales of in-vitro diagnostics. The Company produces and sells in-vitro diagnostics, in-vitro diagnostic equipment and vaccines. The Company is also engaged in the sales of agent products. The in-vitro diagnostics include: enzyme-linked immunosorbent assay (ELISA) reagents, chemiluminescence reagents, biochemical reagents and quality control products. The in-vitro diagnostic instruments mainly include the automatic chemiluminescence immunoassay analyzer. The primary product of vaccine products is Hecolin used for hepatitis E. The agent products are in-vitro diagnostics and in-vitro diagnostic equipment from Bio-Rad Laboratories Inc in the U.S. and Diagast SAS in France.

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

63.4 CNY

Average target price

70.4 CNY

Spread / Average Target

+11.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.1B
CSL LIMITED	-4.66%	87.53B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	40.42B
BIOGEN INC.	-19.07%	29.48B
UCB	+57.86%	25.43B
INCYTE CORPORATION	-17.46%	11.49B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.3B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.75B
INNOVENT BIOLOGICS, INC.	-8.42%	7.99B
INTRA-CELLULAR THERAPIES, INC.	+1.37%	7.67B

Biopharmaceuticals

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Equities

603392

CNE100004090

Pharmaceuticals

Xiamen Innovax Biotech CO., LTD. announced that it has received CNY 400 million in funding from Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Latest news about Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Chart Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals